Securities code: Shenzhen Salubris Pharmaceuticals Co.Ltd(002294) securities abbreviation: Shenzhen Salubris Pharmaceuticals Co.Ltd(002294) No.: 2022024 Shenzhen Salubris Pharmaceuticals Co.Ltd(002294)
Special report on the deposit and use of raised funds in 2021
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
In accordance with the guidelines for the supervision of listed companies No. 2 – regulatory requirements for the management and use of raised funds by listed companies (revised in 2022) issued by the CSRC and the guidelines for the self discipline supervision of listed companies of Shenzhen Stock Exchange No. 1 – standardized operation of companies listed on the main board issued by Shenzhen Stock Exchange, Shenzhen Salubris Pharmaceuticals Co.Ltd(002294) (hereinafter referred to as “the company”) the board of directors prepared a special report on the annual deposit and actual use of the raised funds as of December 31, 2021. It is hereby announced as follows:
1、 Basic information of raised funds
1. Actual amount of funds raised and time of funds in place
With the approval of the reply on the approval of Shenzhen Salubris Pharmaceuticals Co.Ltd(002294) non-public Development Bank shares (zjxk [2021] No. 663 document of the China Securities Regulatory Commission), the company issued Ningbo Ronbay New Energy Technology Co.Ltd(688005) 35 RMB ordinary shares to specific investors, with a par value of 1 yuan per share and an issue price of 28.37 yuan per share. The total amount of funds raised was 1951871200 yuan, after deducting the issuance expenses excluding tax of 19805500 yuan, the net amount of funds actually raised was 1932065700 yuan. All the raised funds were in place on May 24, 2021, and verified and confirmed by Daxin Certified Public Accountants (special general partnership) daxinyz (2021) No. 510001 capital verification report.
2. Use amount and year-end balance of annual raised funds in 2021
As of December 31, 2021, the company has invested 527494500 yuan of raised funds, of which 527494500 yuan has been invested in projects invested with raised funds this year.
As of December 31, 2021, the balance of the company’s fund-raising account is 1420818800 yuan, which is the largest in this year
The accumulated interest income of Du’s raised capital account was 167335 million yuan and the handling fee was 17.00 yuan
Ten thousand yuan.
2、 Deposit and management of raised funds
(I) management of raised funds
In order to strengthen and standardize the management of raised funds, improve the use efficiency of funds and safeguard the legitimate rights and interests of all shareholders
The company law of the people’s Republic of China
Stock listing rules of the stock exchange, self regulatory guidelines for listed companies of Shenzhen Stock Exchange No. 1——
The relevant provisions and requirements of laws, regulations and the articles of association, such as “standardized operation of listed companies on the main board”, shall be combined with
The company has formulated the management measures for Shenzhen Salubris Pharmaceuticals Co.Ltd(002294) raised funds (hereinafter referred to as “the measures”)
Management measures), which was deliberated and adopted at the 16th meeting of the Fifth Board of directors on June 30, 2021
Amendments to the administrative measures.
In accordance with the administrative measures, the company shall store the raised funds in a special account and cooperate with the company’s recommendation institution
Huaying Securities Co., Ltd. and China Merchants Bank Co.Ltd(600036) Shenzhen chegongmiao sub branch and China Minsheng
Nanchang Branch of the Bank of China and Shenzhen Xiangmihu sub branch of Guangdong Development Bank signed the tripartite supervision agreement on raised funds
The company and its subsidiaries Shenzhen Salubris Pharmaceuticals Co.Ltd(002294) (Chengdu) Biotechnology Co., Ltd. and the company’s sponsor Huaying Securities Co., Ltd
Ren company and China Minsheng Banking Corp.Ltd(600016) Shenzhen Branch of China signed the four party supervision agreement on raised funds, which defined the parties
Rights and obligations. The above raised funds supervision agreement and the model tripartite supervision agreement of Shenzhen Stock Exchange do not exist
In terms of significant differences, the performance of these agreements is good at present.
(II) storage of raised funds in special account
As of December 31, 2021, the detailed balance of deposits in the special account for raised funds is as follows:
Unit: RMB
Company name raised funds storage bank name account balance remarks
Shenzhen Shenzhen Salubris Pharmaceuticals Co.Ltd(002294) Pharmaceutical Co., Ltd. has China Merchants Bank Co.Ltd(600036) Shenzhen 7559013591040127637620722 current deposit Co., Ltd. Shenzhen chegongmiao sub branch
Shenzhen Shenzhen Salubris Pharmaceuticals Co.Ltd(002294) Pharmaceutical Co., Ltd. has Nanchang Branch of China China Minsheng Banking Corp.Ltd(600016) Co., Ltd. 63289937350136864975 demand deposit Co., Ltd
Shenzhen Shenzhen Salubris Pharmaceuticals Co.Ltd(002294) Pharmaceutical Co., Ltd. Shenzhen Xiangmihu sub branch of Guangdong Development Bank Co., Ltd. Shenzhen 9550880260720032637617009186 current deposit Co., Ltd
Shenzhen Shenzhen Salubris Pharmaceuticals Co.Ltd(002294) Pharmaceutical Co., Ltd
China China Minsheng Banking Corp.Ltd(600016) Co., Ltd. 63616899726690389418 current deposit Shenzhen Salubris Pharmaceuticals Co.Ltd(002294) (Chengdu) Biotechnology Department Shenzhen Branch Technology Co., Ltd
Total 1420818, 843.01
Note: 48407803 yuan of the balance of 1420818843.01 yuan in the raised funds account was not paid when the raised funds were received
The issuance fee paid.
3、 Actual use of raised funds this year
(I) use of funds for investment projects with raised funds
1. As of December 31, 2021, the company has invested 527494500 yuan of raised funds, including
The investment amount of the raised funds invested in this year is 527494500 yuan.
Investment and benefits of each project
See attached table 1 for details.
2. The 16th meeting of the 5th board of directors of the company on June 30, 2021 deliberated and adopted the
The proposal of using the raised funds to increase capital to Chengdu subsidiary and implement the raised investment project agrees that the company will issue shares in a non-public manner
The raised capital of 263.8 million yuan was transferred to the wholly-owned subsidiary Shenzhen Salubris Pharmaceuticals Co.Ltd(002294) (Chengdu) Biotechnology Co., Ltd
The capital increase is used to implement the “research and development project of innovative drugs in cardiovascular, cerebrovascular and related fields – sal007 recombinant human neural network”
Regulatory protein 1-anti-her3 antibody fusion protein injection phase I / II / III clinical study and listing registration items in China
Construction of “project”. By the end of the reporting period, the capital increase has been completed.
(II) changes in the place and mode of implementation of the project invested with raised funds
As of December 31, 2021, the company does not have the implementation location and implementation of the investment project with raised funds
Change of mode.
(III) advance investment and replacement of investment projects with raised funds
On June 30, 2021, the 16th meeting of the 5th board of directors deliberated and adopted the
The proposal on capital replacement and pre investment of self raised funds agrees that the company will use the funds raised by non-public offering of shares to purchase
The self raised capital of the raised investment project invested in advance is 1297064 million yuan, and the replacement has been completed by the end of the reporting period. See details
Details are as follows:
No. self raised capital invested amount of raised capital investment project raised capital replacement amount (10000 yuan) (10000 yuan)
1 sal0951 enaestat 11508531150853 China Phase I / III clinical research and listing registration project
2 s086 phase II / III clinical research and listing registration project of salkubatra risartan calcium 111175 in China
3 sal0107 alisartan axetil amlodipine compound preparation 307.96 307.96 phase I / III clinical research and listing registration project in China
4 sal0108 alisartan axetil indapamide compound preparation 42.40 42.40 phase I / III clinical research and listing registration project in China
Total 1297064
At the same time, the company used the raised funds to replace the paid issuance expenses of 1.9708 million yuan (excluding tax)
The replacement has been completed by the end of the reporting period. Details are as follows:
No. category self raised fund invested amount raised fund replacement amount
(10000 yuan) (10000 yuan)
1 recommendation service 113.21 113.21
2 lawyer services 67.63 67.63
Capital verification 68.3
4 issuing legal opinions 8.98 8.98
5 material fabrication 3.58 3.58
Total 197.08 197.08
(IV) temporary replenishment of working capital with idle raised funds
As of December 31, 2021, the company has not temporarily replenished working capital with idle raised funds
Situation.
(V) cash management with idle raised funds
On June 30, 2021, the 16th meeting of the 5th board of directors of the company deliberated and adopted the
The company and its wholly-owned subsidiaries (investment projects with raised funds) are approved according to the proposal on cash management of idle raised funds
Affiliated companies) use idle raised funds of no more than RMB 800 million for cash management, and the above amount can be
It is jointly used and authorized by the company and its wholly-owned subsidiary (the company of the raised funds investment project)
The management is responsible for the specific implementation of relevant matters, and the authorization period is within one year from the date of deliberation and approval of this board of directors
Effective. As of the end of the reporting period, the matter had not been implemented.
(VI) use of surplus raised funds
As of December 31, 2021, the company has not used the surplus funds of raised funds investment projects for other raised funds investment projects or non raised funds investment projects.
(VII) use of over raised funds
The company has no over raised funds in this non-public offering.
(VIII) purpose and destination of unused raised funds
As of December 31, 2021, the unused raised funds and interest are stored in a special account and used according to the investment plan of the raised funds.
(IX) other information about the use of raised funds
None.
4、 Change the use of funds for investment projects with raised funds
As of December 31, 2021, the company has no
